Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)
Effects of Ivacaftor (Kalydeco) Treatment Upon Insulin and Incretin Secretion in Patients With Cystic Fibrosis
Sponsor: Children's Hospital of Philadelphia
A observational or N/A phase clinical study on Cystic Fibrosis and Cystic Fibrosis Related Diabetes, this trial is completed. The trial is conducted by Children's Hospital of Philadelphia and has accumulated 8 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jan 2019 — Jan 2021 [monthly]
Completed
Status: Recruiting → Completed
-
Jun 2018 — Jan 2019 [monthly]
Recruiting
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Hospital of Philadelphia
For direct contact, visit the study record on ClinicalTrials.gov .